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While type-I interferons (IFNs) play critical roles in
antiviral and antitumor activity, it remains to be eluci-
dated how type-I IFNs are produced in sterile conditions
of the tumor microenvironment and directly impacts
tumor-infiltrating immune cells. We report that both
human and de novo mouse gliomas show increased
expression of type-I IFN messages, and in mice, CD11b+
brain-infiltrating leukocytes (BILs) are the main source
1Department of Neurological Surgery, University of Pittsburgh School of
Medicine, Pittsburgh, PA
Figure 1 Type-I IFNs directly impact on T-cell functions in glioma-developing mice. (A) CD4+ cells from draining LN derived from glioma-
developing tdTomato mice were sorted into GFP- or GFP+ cells and incubated with (black bars) or without (grey bars) anti-CD3mAb. After 4 h,
total RNA was extracted for evaluation of Foxp3 and Tgfb1 mRNA levels by qRT-PCR. (B) CFSE-labeled WT CD8+ T-cells were co-cultured with
GFP- or GFP+ CD4+ T-cells in the presence of CD3 beads. After 60 h, division of CFSE-labeled CD8+ T-cells gated by reactivity to PE-Cy7-
condjugated anti-CD8mAb was evaluated by CFSE intensity. As a negative control, CFSE-labeled WT CD8+ T-cells were cultured without any
stimulation (left panel). Histograms are representative of two independent experiments. The bar graph shows the percentage of CD8+ cells that
have divided at least twice in each of two stimulation conditions (N = 4/group; *p < 0.05). (C) GFP- or GFP+ CD8+ T-cells were incubated with
(black bar) or without (grey bar) anti-CD3mAb. After 4 h, total RNA was extracted for evaluation of Tbx21 and Ifng mRNA expression levels by
qRT-PCR (U: undetected). (D) Cytotoxic activity of GFP- and GFP+ CD8+ T-cells was evaluated by 51Cr-release assay. RMA-S cells untreated (left
panel) or pretreated (right panel) with anti-CD3mAb (10 g/mL) were used as target cells. *p < 0.05 compared at the same E/T ratio.
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of type-I IFNs that is induced partially in a STING
(stimulator of IFN genes)-dependent manner. Conse-
quently, glioma-bearing StingGt/Gt mice showed shorter
survival, and lower expression levels of Ifns compared
with wild-type mice. Furthermore, BILs of StingGt/Gt
mice show increased CD11b+ Gr-1+ immature myeloid
suppressor and CD25+ Foxp3+ regulatory T (Treg) cells,
while decreased IFN-g-producing CD8+ T cells. To
determine the effects of type-I IFN expression in the
glioma microenvironment, we utilized a novel reporter
mouse model, in which the type-I IFN signaling induces
the Mx1 (IFN-induced GTP-binding protein) promoter-
driven Cre recombinase, which turns the expression of
loxp-flanked tdTomato off, and turns green fluorescence
protein (GFP) expression on, thereby enabling us to
monitor the induction and effects of IFN signaling in
the glioma microenvironment. CD4+ T cells that
received direct type-I IFN signals (i.e., GFP+ cells)
demonstrate lesser degrees of regulatory activity based
on lower Foxp3 and Tgfb1 expression levels (Figure 1)
as well as lesser suppression of CD8+ T cell proliferation
(Figure B). IFN-sensed CD8+ T cells exhibit enhanced
levels of Th1 markers, Tbx21 and Igfng (Figure C),
as well as cytotoxic T-cell activity based on reverse
antibody-dependent T-cell-mediated cytotoxicity assay
(Figure D). Finally, intratumoral administration of a
STING agonist (cyclic diguanylate monophosphate; c-di-
GMP) improves the survival of glioma-bearing mice
associated with enhanced type-I IFN signaling, Cxcl10 and
Ccl5 and T cell migration into the brain. In a combination
with subcutaneous OVA peptide-vaccination, c-di-GMP
increased OVA-specific cytotoxicity of BILs and prolonged
the survival. These data demonstrate significant contribu-
tions of STING to antitumor immunity via enhancement
of the type-I IFN signaling in the tumor microenviron-
ment, and imply a potential use of STING agonists for
development of effective immunotherapy, such as the
combination with antigen-specific vaccinations.
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